RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Prostate Cancer Channel

subscribe to Prostate Cancer newsletter
Latest Research : Cancer : Prostate Cancer

   EMAIL   |   PRINT
Delaying radiation for prostate cancer does not affect outcome

Jun 14, 2005 - 6:09:00 AM
The investigators found that there was no difference in overall survival, disease specific survival, the incidence of distant metastases, and treatment failure for men who delayed 3DCRT more than nine months. Moreover, there was no difference in outcome for men with low-, intermediate-, and high-risk tumors who delayed treatment less than or more 3 months.

 
[RxPG] For men diagnosed with prostate cancer, there is no risk of recurrence if external beam radiation therapy (EBRT) is delayed by several months. A study published in the July 15, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, finds delays of EBRT had no harmful impact on clinical outcome or biochemical marker levels in low-, intermediate- and high-risk patients.

Prostate cancer is generally a slow-developing malignancy that affects older men. However, treatment is still important for survival and includes surgery and radiation. The forms of available radiotherapy include external beam radiation – 3D conformal radiation therapy (3DCRT), intensity modulated radiation therapy, or brachytherapy. Treatment delays of several months are quite common for men diagnosed with prostate cancer and can cause patients concern and anxiety.

While radiation treatment delays in other cancers are associated with increased mortality, little is known about the effect of delaying treatment on the outcome of prostate cancer. Stephen F. Andrews, D.O. and colleagues from the Fox Chase Cancer Center in Philadelphia reviewed the data from almost 1500 men treated for locally confined prostate cancer to investigate the effect of 3DCRT delay on outcome.

The investigators found that there was no difference in overall survival, disease specific survival, the incidence of distant metastases, and treatment failure for men who delayed 3DCRT more than nine months. Moreover, there was no difference in outcome for men with low-, intermediate-, and high-risk tumors who delayed treatment less than or more 3 months.

For men with locally confined prostate cancer, "patients and physicians can use this information to alleviate concerns and anxiety regarding delaying treatment in order to make a well-informed treatment decision," conclude the authors.



Publication: "Does a Delay In External Beam Radiation Therapy after Tissue Diagnosis Affect Outcome for Men with Prostate Carcinoma?," Stephen F. Andrews, Eric M. Horwitz, Steven J. Feigenberg, Debra F. Eisenberg, Alexandra L. Hanlon, Robert G. Uzzo, Alan Pollack, CANCER; Published Online: June 13, 2005 (DOI: 10.1002/cncr.2184); Print Issue Date: July 15, 2005.
On the web: http://www.interscience.wiley.com/ 

Advertise in this space for $10 per month. Contact us today.


Related Prostate Cancer News
Abiraterone has been approved for men with metastatic prostate cancer that is no longer responsive to therapy with hormones and docetaxel
Virus associated with prostate cancer tumors and chronic fatigue syndrome unlikely to be the cause
Acupuncture helps with side effects of prostate cancer treatment
Surgery superior to drug therapy for symptoms of benign prostatic hypertrophy
Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer
Inhibition of TNF-receptor associated protein-1possible treatment for prostatic cancer
Oncologists present test to predict survival in castration-resistant prostate cancer patients
PSA levels appear to be predictive of three year prostate cancer risk in African-American men
Survey on PSA screening in young men
New, noninvasive prostate cancer test beats PSA in detecting prostate cancer

Subscribe to Prostate Cancer Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)